Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Hui Chen Image

      Hui Chen, M.D., Ph.D.

      Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div

      About Dr. Hui Chen

      I am a board-certified pathologist specialized in Molecular Genetics Pathology and Breast Pathology. My research interest is to study actionable genetic alterations in advanced solid tumors and their predications for therapeutic intervention. I work with molecular diagnostic laboratory, breast pathology, and cytogenetics teams on various quality improvement projects to improve the overall performance of immunohistochemistry and genotype platforms including next-generation sequencing for clinical molecular diagnostics. I participate in multiple clinical test development/validations of biomarker testing for solid tumors. I am co-medical director of Clinical Trial Operation to oversee test validation and customized tests of novel biomarkers for clinical trials at MD Anderson and nationwide. The accurate interpretation of biomarkers in cases with borderline and conflicting results can be extremely challenging. I am interested in improving the interpretation accuracy of biomarkers i.e. ER, PR, HER2, and PTEN in cases with borderline and conflicting results using alternative test platform to guide treatment decision for personalized cancer therapy.  During my career at MD Anderson, I have worked closely oncologists and scientists in various translational research projects to better understand tumor biology. 

      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Pathology, The University of Texas MD Anderson Cancer Center

      Dual/Joint/Adjunct Appointment

      Professor, The University of Texas Medical Branch Health

      Professor, Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2001Colorado State University, Fort Collins, Colorado, US, Biochemistry and Molecular Biology, PhD
      1994Peking Union Medical College, Beijing, CN, MD

      Postgraduate Training

      2012-2013Clinical Fellowship, Molecular Genetic Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
      2011-2012Clinical Fellowship, Oncologic Surgical Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
      2007-2011Clinical Residency, Anatomic and Clinical Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
      2005-2006Research Fellowship, Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland
      2001-2005Research Fellowship, Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland

      Licenses & Certifications

      2014American Board of Pathology, Molecular Genetic Pathology
      2013Texas Medical Board
      2012American Board of Pathology, Anatomic Pathology and Clinical Pathology
      2011New York State Education Department Board of Medicine
      2007New Hampshire Board of Medicine

      Experience & Service

      Faculty Academic Appointments

      Associate Professor (Joint appointment), The University of Texas Medical Branch Health, Houston, TX, 2019 - 2025

      Associate Professor, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025

      Assistant Professor, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019

      Physician, Peking Union Medical College Hospital, Beijing, 1994 - 1995

      Administrative Appointments/Responsibilities

      Medical Director, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

      Associate Medical Director, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Breast Pathology Fellowship PEC/CCC Chair, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025

      Co-Medical Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024

      Other Professional Positions

      Solid Tumors Nominating Committee Representative, Association for Molecular Pathology, Rockville, Minnesota, 2025 - 2027

      Associate Editor, Compendium of Cancer Genomic Abnormalities, N/A, 2022 - Present

      Co-Chair, Cancer Genomics Consortium Breast Cancer Working Group, N/A, 2022 - Present

      Committee Member, Cancer Genomics Consortium Breast Cancer Working Group, N/A, 2017 - Present

      Committee Member, Compendium of Cancer Genomic Abnormalities, Charleston, SC, 2016 - Present

      Ambassador, USCAP, Palm Springs, CA, 2016 - 2018

      Extramural Institutional Committee Activities

      Committee Member, Molecular Genetic Pathology Fellowship PEC, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Committee member, PRS Budget & Finance Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025

      Committee Member, Surgical Pathology Fellowship CCC, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Committee Member, Clinical Genomics and Biomarker Council (CGC), The University of Texas MD Anderson Cancer Center, 2020 - Present

      Committee member, Molecular Testing Evaluation Committee (MTEC), The University of Texas MD Anderson Cancer Center, 2020 - Present

      Committee member, PRS Leadership & Institutional Service Award (L.I.S.A) Nomination Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2020

      Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2018 - 2021

      Committee Member, PRS Faculty Compensation & Benefit Advisory Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2021

      Committee Member, Fellow Lecture Evaluation and Awards Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2023

      Editorial Activities

      USCAP Abstract Review Board member, Modern Pathology, 2018 - 2020

      Editorial Board Member, Journal of Pathology & Microbiology, 2015 - Present

      Editorial Board Member, Diagnostic Pathology: Open Access, 2015

      Honors & Awards

      2018Highlights in Molecular Cancer Therapeutics
      2009CAP First Place Junior Member Abstract
      2003 - 2005American Heart Association research award
      1998American Society for Cell Biology travel award
      1994Peking Union Medical College Hospital excellent resident award

      Professional Memberships

      American Association for Cancer Research

      2025 - Present

      Cancer Genomics Consortium

      2015 - Present

      Texas Medical Association

      2014 - 2016

      Association for Molecular Pathology

      2013 - Present

      American Medical Association

      2010 - 2015

      United States and Canadian Academy of Pathology

      2008 - Present

      College of American Pathologists

      2007 - Present

      American Society for Cell Biology

      2002 - 2006

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Breast cancer biomarker testing: updates, obstacles, and future direction. Invited. The William O. Russell Annual Conference: Nuts & Bolts in Surgical Pathology. Houston, Texas, US.
      2. 2024. Breast Cancer Biomarker Testing. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      3. 2023. HER2 Testing - Current Status and Future Directions. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      4. 2022. Practical Approach to Solid Tumor Molecular Diagnostics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      5. 2022. Tissue Qualification for Solid Tumor Molecular Diagnostics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      6. 2022. Introduction to Solid Tumor Molecular Diagnostics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      7. 2022. Breast Cancer Biomarkers. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
      8. 2018. Special Tricks for Special Needs: Biomarker Request. Invited. MD Anderson Cancer Center. Houston, TX, US.
      9. 2018. HER2 Testing Current Status and Future Directions. Conference. MD Anderson Cancer Center. Houston, TX, US.

      Regional Presentations

      1. 2024. Solid Tumor Molecular Diagnostics. Invited. The University of Texas MD Anderson Cancer Center. Houston, US.
      2. 2023. Tissue Qualification for Solid Tumor Molecular Diagnostics. Invited. The University of Texas MD Anderson Cancer Center. Houston, US.
      3. 2018. Molecular Pathology of Breast Cancer. Invited. University of Texas Health Science Center at Houston. Houston, TX, US.
      4. 2016. HER2 Assessment by MIP Microarray in a Breast Cancer Patient with Equivocal HER2 Status. Invited. Houston Society of Clinical Pathologists. Houston, TX, US.
      5. 2015. Quantitative Assessment of HER2 Copy Number in Breast Cancer by MIP Microarray. Invited. The University of Texas MD Anderson Cancer Center School of Health Professions. Houston, TX, US.

      National Presentations

      1. 2025. ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics. Poster. USCAP 114TH. BOSTON, MA, US.
      2. 2025. Tumor Mutational Burden High Breast Cancer: Correlation with Clinicopathological and Co-existing Molecular Characteristics. Conference. UACAP. BOSTON, MA, US.
      3. 2025. Recurring Genes in Fusions in Advanced Breast Carcinoma Detected by Next Generation Sequencing: Novel BCR and TMPRSS2 Gene Fusions. Conference. USCAP. BOSTON, MA, US.
      4. 2025. Clinicopathological and Molecular Characteristics of Metastatic Breast Cancer: Comparison of Metastatic Sites. Poster. USCAP 114TH ANNUAL MEETING. Boston, ma, US.
      5. 2025. Tumor Mutational Burden High Breast Cancer: Correlation with Clinicopathological and Co-existing Molecular Characteristics. Poster. USCAP 114th annual Meeting. Boston, MA, US.
      6. 2025. GATA3 and TRPS1 Expression in Follicular Dendritic Cell Sarcoma. Poster. USCAP 114th. Boston, MA, US.
      7. 2025. Optimizing TROP2 Immunohistochemistry Scoring by Automated Quantitative Image Analysis for Generating Clinical Trial-Driven IHC Scores. Poster. USCAP 114th. Boston, MA, US.
      8. 2025. Clinicopathologic and Molecular Characterization of BRAF-Fused Melanomas: A Retrospective Analysis of 9 Cases with 8 Novel Fusions Detected by Next-Generation Sequencing. Poster. USCAP 114th. Boston, MA, US.
      9. 2025. ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics. Conference. USCAP. Boston, MA, US.
      10. 2025. Clinicopathological and Molecular Characteristics of Metastatic Breast Cancer: Comparison of Metastatic Sites. Conference. USCAP. Boston, MA, US.
      11. 2025. Unraveling the Nexus: Tumor Mutational Burden, PD-L1 Expression and Oncogene Specific Alterations in Cytology Specimens of Non-Small Cell Lung Cancer. Conference. USCAP. Boston, MA, US.
      12. 2025. Clinicopathologic and Molecular Characterization of BRAF-Fused Melanomas: A Retrospective Analysis of 9 Cases with 8 Novel Fusions Detected by Next-Generation Sequencing. Conference. USCAP. BOSTON, MA, US.
      13. 2025. GATA3 and TRPS1 Expression in Follicular Dendritic Cell Sarcoma. Conference. USCAP. BOSTON, MA, US.
      14. 2025. Optimizing TROP2 Immunohistochemistry Scoring by Automated Quantitative Image Analysis for Generating Clinical Trial-Driven IHC Scores. Conference. USCAP. BOSTON, MA, US.
      15. 2017. Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray. Invited. Cancer Genomics Consortium 2017 Summer. Denver, CO, US.
      16. 2017. Molecular Diagnostics of Solid and Pre-analytical Factors Affecting the Success of Next Generation Sequencing in Solid Tumors. Invited. Western New York Society of Pathologists. Buffalo, NY, US.
      17. 2016. Solid tumor molecular diagnostics in personalized care of cancer patients. Invited. Dartmouth-Hitchcock Medical Center. Lebanon, NH, US.
      18. 2015. Clinical opportunities of SNP microarray in solid tumors. Invited. GTCBio. San Diego, CA, US.
      19. 2014. KRAS Amplification In A 73 Year-Old-Man With Adenocarcinoma Of Lung. Invited. CGC-CAGdb. Chicago, IL, US.
      20. 2013. ALK Point Mutations in Neuroblastoma: Association with Poorly Differentiated Morphology. Invited. Society for Pediatric Pathology. Baltimore, MD, US.
      21. 2003. Ligand-specific alterations of the structure of vinculin tail revealed by FRET. Invited. The Federation of American Societies for Experimental Biology. San Diego, CA, US.
      22. Recurring Genes in Fusions in Advanced Breast Carcinoma Detected by Next Generation Sequencing: Novel BCR and TMPRSS2 Gene Fusions. Poster. USCAP 114th. Boston, MA, US.
      23. Unraveling the Nexus: Tumor Mutational Burden, PD-L1 Expression and Oncogene Specific Alterations in Cytology Specimens of Non-Small Cell Lung Cancer. Poster. USCAP 114th. Boston, MA, US.

      International Presentations

      1. 2024. TROP2 Immunohistochemical Assay in Solid Tumors: Comparison of Interpretation Scoring Assessments by H-score and Clinical Trial-Driven ADC-score. Invited. United States and Canadian Academy of Pathology. Baltimore, US.
      2. 2018. Molecular Diagnostics in Solid Tumors. Invited. The 7th Biennial MD Anderson Cancer Center and China Sister Institutes Pathology Conference. Changsha, CN.
      3. 2017. Breast Cancer and Molecular Diagnostics. Invited. China Japan Friendship Hospital. Beijing, CN.
      4. 2017. Breast Carcinoma and Its Mimickers. Invited. PLA General Hospital. Beijing, CN.
      5. 2017. Next generation sequencing in personalized care of cancer patients. Invited. The Asia Pacific International Academy of Pathology. Bali, ID.
      6. 2017. Diagnostic challenges in breast cancer. Invited. Peking Union Medical College Hospital. Beijing, CN.
      7. 2016. Molecular Diagnostics of Breast Cancer. Invited. Annual Conference of Beijing Breast Disease. Beijing, CN.
      8. 2016. Clinical Opportunities of SNP Microarray in Breast Cancer. Invited. 2nd World Congress on Breast Cancer. Phoenix, US.
      9. 2016. Pre-analytical Factors Affecting the Success of Next-Generation Sequencing in Solid Tumors. Invited. 5th International Conference on Pathology. Chicago, US.
      10. 2016. Assessment of HER2 Copy Number in Breast Cancer by MIP Microarray. Invited. PLA General Hospital. Beijing, CN.
      11. 2015. Current Advances in Molecular Diagnostics of Solid Tumors. Invited. 1st Sino-US Cancer Diagnostic Pathology Summit. Beijing, CN.
      12. 2015. Clinical Opportunities of SNP Microarray in Solid Tumors. Invited. Peking Union Medical College Hospital. Beijing, CN.
      13. 2015. Tissue Qualification and Molecular Diagnostics in Solid Tumors. Invited. PLA General Hospital. Beijing, CN.
      14. 2014. Molecular diagnostics in solid tumors. Invited. Peking Union Medical College Hospital. Beijing, CN.

      Formal Peers

      1. 2023. Tissue Qualification for Solid Tumor Molecular Diagnostics. Visiting. Houston, TX, US.
      2. 2023. Solid Tumor Molecular Diagnostics. Conference. Houston, US.
      3. 2023. Breast Cancer Biomarker Request for Molecular Testing. Conference. Houston, US.
      4. 2022. Solid Tumor Molecular Diagnostics. Conference. Houston, US.
      5. 2022. Breast Cancer Biomarker Request for Molecular Testing. Conference. Houston, US.
      6. 2021. Breast Cancer Biomarker Request for Molecular Testing. Conference. Houston, US.
      7. 2020. Breast Cancer Biomarker Request for Molecular Testing. Conference. Houston, US.
      8. 2019. Breast Cancer Biomarker Request for Molecular Testing. Conference. Houston, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2031
      Title:AI Pathology‑Enhanced Chromatin Profiling of FFPE Tissue for Precision Prognosis
      Funding Source:NATIONAL INSTITUTES OF HEALTH
      Role:Co-I
      ID:FP00027424
      Date: 2025 - 2025
      Title:Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis
      Funding Source:NCI
      Role:Collaborator
      Date: 2025 - 2027
      Title:Delineating Multi-Organ Metastasis in Triple Negative Breast Cancer with Single Cell Genomics
      Funding Source:ACS
      Role:Collaborator
      Date: 2023 - 2025
      Title:20-089F3 – Lab Readiness, ImmunoMATCH Assays and ComboMATCH Assays
      Funding Source:NIH/NCI
      Role:Co-PI
      Date: 2022 - 2025
      Title:S20-089F2 ComboMATCH
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:75N91019D00024
      Date: 2022 - 2025
      Title:Continuation of IFA Support
      Funding Source:NIH/NCI
      Role:Co-I
      ID:75N91019D00024
      Date: 2022 - 2024
      Title:NCLN NGS IHC Implementation
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:75N91019D00024
      Date: 2022 - 2023
      Title:Human Breast Cell Atlas Seed Network
      Funding Source:Silicon Valley Community Foundation
      Role:Collaborator
      ID:2022-246364
      Date: 2022 - 2026
      Title:De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
      Funding Source:NRG
      Role:Collaborator
      ID:NRG-BR007
      Date: 2022 - 2023
      Title:S20-089F1 MDNet - Site Management
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:20X089
      Date: 2021 - 2022
      Title:Molecular Profiling of Malignant Spindle Cell Lesions of the Breast: Genetic Alterations of Spindle Cell Metaplastic Carcinoma and Malignant Phyllodes Tumor
      Funding Source:MD Anderson Department Chair’s Funds for Mentored Trainee Research
      Role:PI
      Date: 2020 - 2021
      Title:PTEN Loss in ER+ Breast Cancer
      Funding Source:MD Anderson Department Chair’s Funds for Mentored Trainee Research
      Role:PI
      Date: 2020 - 2023
      Title:Admin Main Award Texas EXper
      Funding Source:NIH/NCI
      Role:Collaborator
      ID:2UM1CA186688-06
      Date: 2019 - 2022
      Title:Human Breast Cell Atlas Seed Network
      Funding Source:Chan Zuckerberg Foundation
      Role:Collaborator
      ID:FP00008028 / CZF2019-002432
      Date: 2019 - 2025
      Title:NCTN Patient Accruals
      Funding Source:NIH/NCI
      Role:Collaborator
      ID:5UG1CA233329-04
      Date: 2018 - 2019
      Title:HER2 testing in breast cancer patients with monosomy of CEP17 in group 2
      Funding Source:MD Anderson Department Chair’s Funds for Mentored Trainee Research
      Role:PI
      Date: 2018 - 2024
      Title:Admin Core: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Collaborator
      ID:RP180712
      Date: 2018 - 2024
      Title:Core 2: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:Collaborator
      ID:FP00006617
      Date: 2017 - 2018
      Title:The Human Breast Cell Atlas
      Funding Source:The Silicon Valley Community Foundation (SVCF)
      Role:Collaborator
      ID:173955 Chan Zuckerberg Initiative DAF
      Date: 2015 - 2015
      Title:Molecular Evaluation of HER2 gene Amplification in Patients with Borderline Result by Conventional Methods
      Funding Source:MD Anderson Department of Pathology Seed Grant
      Role:PI
      Date: 2003 - 2005
      Title:American Heart Association postdoctoral research grant
      Funding Source:American Heart Association
      Role:PI
      ID:0325527U
      Title:Precision ADC Therapy with Multiplex RNA Assays and Digital Pathology for Targeted Selection
      Funding Source:NIH/NCI
      Role:PI
      ID:14177984

      Selected Publications

      Peer-Reviewed Articles

      1. Roy-Chowdhuri S, Galan-Cobo A, Agarwal N, Arias J, Ballester LY, Chen H, Kulkarni S, Patel KP, Routbort MJ, Chen S, Chen W, Duose D, Floyd K, Koci C, McAndrew W, Ninan S, Robinson M, San Lucas FA, Seyedjafari R, Zhang NJ, Kanagal-Shamanna R, Luthra R. Analytical Validation of a Plasma-Based Rapid Liquid Biopsy Assay Using Next-Generation Sequencing. J Mol Diagn, 2026. e-Pub 2026. PMID: 42532207.
      2. Atwell H, Roy-Chowdhuri S, Seyedjafari R, Hill H, Du L, Zhang J, Koci C, Palmer A, Mendoza Y, Ma S, Hu Y, Flores N, Bryan J, Chen H, Luthra R, Ballester LY, Patel KP, Kulkarni S, Sura GH. The Critical Role of Preanalytical Factors in Validating Cytology Specimens for Hybrid-Capture Next-Generation Sequencing: From Smear to Sequence. J Mol Diagn, 2026. e-Pub 2026. PMID: 42480848.
      3. Ye H, McDonald TO, Elghaish R, Sei E, Conterno Minussi D, Hu M, Bai S, Tang C, Wang J, Wang K, Downey RJ, Casasent A, Nicholson MD, Chen H, Michor F, Navin NE. A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution. Cancer Discov, 2026. e-Pub 2026. PMID: 42258702.
      4. Roy-Chowdhuri S, Agarwal N, Gulraiz F, Ballester L, Chen H, Kanagal-Shamanna R, Kulkarni S, Patel KP, Sura G, Zhang NJ, Luthra R. Analytical validation of a rapid next generation sequencing-based liquid biopsy assay using fine needle aspiration supernatants for clinical use. J Am Soc Cytopathol, 2026. e-Pub 2026. PMID: 42309846.
      5. Dai, M, San Lucas, FA, Alvarez, HA, Ballester, L, Chen, H, Patel, KP, Rashid, A, Rao, S, Routbort, MJ, Sura, GH, Sweeney, K, Toruner, GA, Wei, P, Yang, RK, Dang, HD, Luthra, R, Roy Chowdhuri, S. Unraveling the nexus. Cancer Cytopathology 134(4), 2026. e-Pub 2026. PMID: 41891376.
      6. Wang, J, Minussi, DC, Davis, A, Wei, R, Ye, H, Sei, E, Schalck, A, Yan, Y, Wu, HJ, Bai, S, Peng, C, Hu, M, Casasent, A, Contreras, A, Chen, H, Hui, D, Damodaran, S, Edgerton, ME, Kopetz, S, Lim, B, Navin, N. Delineating the copy-number substructure of metastatic tumors with CopyKit. Molecular cell 86(2):407-422.e6, 2026. e-Pub 2026. PMID: 41534520.
      7. Adesoye T, Dumbrava EE, Raghav KPS, Sahin AA, Chen H, Lee SS, Javle MM, Pant S, Alhalabi O, Le X, Valero V, Pohlmann PR, Meric-Bernstam F. Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach. Clin Cancer Res 32(2):260-290, 2025. e-Pub 2025. PMID: 41283902.
      8. Ye Q, Estrella J, Kalhor N, Liu A, Han C, Sun H, Middleton LP, Chen H, Albarracin C, Sahin A, Wu Y, Ding Q. TRPS1 expression in neuroendocrine neoplasms of breast and other organs. Histopathology 88(2):524-532, 2025. e-Pub 2025. PMID: 41025885.
      9. Shen, Y, Zheng, L, Zhao, J, Wang, Y, Chen, H, Roy Chowdhuri, S, Kamat, A, Alhalabi, O, Gao, J, Siefker-Radtke, AO, Wei, P, Hansel, DE, Czerniak, BA, Guo, CC. Molecular profile of micropapillary urothelial carcinoma of the urinary bladder. Human Pathology 159, 2025. e-Pub 2025. PMID: 40403852.
      10. Wang P, Yang RK, Jelloul FZ, Luthra R, Routbort MJ, Chen H, Loghavi S, Ok CY, Kanagal-Shamanna R, Roy-Chowdhuri S, Medeiros LJ, Patel KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precis Oncol 9:e2400299, 2025. e-Pub 2025. PMID: 40138600.
      11. Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
      12. Ye Q, Law T, Klippel D, Albarracin C, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans WF, Wu Y, Yoon E, Krishnamurthy S. Prospective and Retrospective Analysis of Whole-Slide Images of Sentinel and Targeted Lymph Node Frozen Sections in Breast Cancer. Mod Pathol 38(4):100708, 2025. e-Pub 2025. PMID: 39788205.
      13. Yang, RK, Alvarez, HA, Lucas, AS, Roy Chowdhuri, S, Rashid, A, Chen, H, Ballester, L, Sweeney, K, Routbort, MJ, Patel, KP, Luthra, R, Medeiros, LJ, Toruner, GA. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genetics 290-291:44-50, 2025. e-Pub 2025. PMID: 39700818.
      14. Huang, ML, Lane, DL, Chang Sen, LQ, Candelaria, RP, Kuerer, HM, Hunt, KK, Akay, C, Lim, B, Shaitelman, S, Hwang, RF, Chen, H, Katta, R, Santiago, L. Defining Breast Cryoablation Treatment Success. Academic radiology 31(12):4759-4771, 2024. e-Pub 2024. PMID: 39107186.
      15. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear Staining for Pan-Trk by Immunohistochemistry Is Highly Specific for Secretory Carcinoma of breast: Pan-Trk in Various Subtypes of Breast Carcinoma. J Clin Pathol 77(11):751-755, 2024. e-Pub 2023. PMID: 37586834.
      16. Batra, H, Bose, PC, Ding, Y, Dai, A, Chen, H, Albarracin, C, Sun, H, Sahin, AA, Yang, F, Wistuba, II, Raso, G. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology 85(3):503-509, 2024. e-Pub 2024. PMID: 38973399.
      17. Yu Y, Cao WM, Cheng F, Shi Z, Han L, Yi J, da Silva EM, Dopeso H, Chen H, Yang J, Wang X, Zhang C, Zhang H. FOXK2 amplification promotes breast cancer development and chemoresistance. Cancer Lett 597:217074, 2024. e-Pub 2024. PMID: 38901667.
      18. Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat AM, Alhalabi O, Gao J, Siefker-Radtke A, Hansel DE, Czerniak B, Guo CC. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol 148:1-6, 2024. e-Pub 2024. PMID: 38679207.
      19. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat 205(2):403-411, 2024. e-Pub 2024. PMID: 38441847.
      20. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
      21. Diks J, Tang Z, Altan M, Anderson S, Chen H, Rashid A, Yang RK, Routbort MJ, Patel KP, Toruner GA, Medeiros LJ, Tang G, Luthra R, Roy-Chowdhuri S. Detection of Clinically Actionable Gene Fusions by Next-Generation Sequencing-Based RNA Sequencing of Non-Small Cell Lung Cancer Cytology Specimens: A Single Center Experience with Comparison to Fluorescence in Situ Hybridization. Cancer Cytopathol 132(1):41-49, 2024. e-Pub 2024. PMID: 37747438.
      22. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX Scores in Synchronous Bilateral and Unilateral Multifocal Breast Cancers. Breast Cancer Res Treat 203(1):73-83, 2024. e-Pub 2024. PMID: 37751078.
      23. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1):6, 2023. e-Pub 2023. PMID: 38201434.
      24. Yang L, Lin H, Shen Y, Roy M, Albarracin C, Ding Q, Huo L, Chen H, Wei B, Bu H, Bedrosian I, Wu Y. Clinical Outcome and Therapeutic Impact on Neuroendocrine Neoplasms of the Breast: A National Cancer Database Study. Breast Cancer Res Treat 202(1):23-32, 2023. e-Pub 2023. PMID: 37566192.
      25. Kumar T, Nee K, Wei R, He S, Nguyen QH, Bai S, Blake K, Pein M, Gong Y, Sei E, Hu M, Casasent AK, Thennavan A, Li J, Tran T, Chen K, Nilges B, Kashikar N, Braubach O, Ben Cheikh B, Nikulina N, Chen H, Teshome M, Menegaz B, Javaid H, Nagi C, Montalvan J, Lev T, Mallya S, Tifrea DF, Edwards R, Lin E, Parajuli R, Hanson S, Winocour S, Thompson A, Lim B, Lawson DA, Kessenbrock K, Navin N. A spatially resolved single cell genomic atlas of the adult human breast. Nature 620(7972):181-191, 2023. e-Pub 2023. PMID: 37380767.
      26. Dogan S, Xu B, Rana S, Chen H, Ghossein RA, Berger MF, Ho AL, Katabi N. Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. Mod Pathol 36(7):100150, 2023. e-Pub 2023. PMID: 36841437.
      27. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer with a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
      28. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
      29. Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, Patel KP, Luthra R, Medeiros LJ, Toruner GA. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel) 14(19), 2022. e-Pub 2022. PMID: 36230473.
      30. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol 158(2):263-269, 2022. e-Pub 2022. PMID: 35467000.
      31. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
      32. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic nonhematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
      33. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
      34. Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, ChenH, Rashid A, Lazar A, Lucas FAS, Yao H, Manekia J, Dang H, Barkoh BA, Medeiros LJ, Luthra R, Roy-Chowdhuri S. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med 145(11):1405-1412, 2021. e-Pub 2021. PMID: 33493304.
      35. Huang X, Chen H, Ding Q, Robinson MK, Moseley TW, Bassett RL, Tang G, Lim B, Sahin AA. Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma. Hum Pathol 117:51-59, 2021. e-Pub 2021. PMID: 34363799.
      36. Wang K, Xiao Z, Yan Y, Ye R, Hu M, Bai S, Sei E, Qiao Y, Chen H, Lim B, Lin SH, Navin NE. Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility. Mol Cell 81(20):4319-4332.e10, 2021. e-Pub 2021. PMID: 34686316.
      37. McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat 187(1):95-104, 2021. e-Pub 2021. PMID: 33813685.
      38. Ramani NS, Chen H, Broaddus RR, Lazar AJ, Luthra R, Medeiros LJ, Patel KP, Rashid A, Routbort MJ, Stewart J, Tang Z, Bassett R, Manekia J, Barkoh BA, Dang H, Roy-Chowdhuri S. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol 129(5):374-382, 2021. e-Pub 2021. PMID: 33119213.
      39. Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani A, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-308, 2021. e-Pub 2021. PMID: 33762732.
      40. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2021. PMID: 33011748.
      41. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat 186(2):403-415, 2021. e-Pub 2021. PMID: 33528758.
      42. Sun H, Chen H, Crespo J, Tang G, Robinson M, Lim B, Sahin AA. Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy. Eur J Breast Health 17(2):128-136, 2021. e-Pub 2021. PMID: 33870112.
      43. Shah M, Takayasu T, Zorofchian Moghadamtousi S, Arevalo O, Chen M, Lan C, Duose D, Hu P, Zhu JJ, Roy-Chowdhuri S, Riascos RF, Chen H, Luthra R, Esquenazi Y, Ballester LY. Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies. J Mol Diagn 23(2):171-180, 2021. e-Pub 2021. PMID: 33531134.
      44. Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol 108:42-50, 2021. e-Pub 2021. PMID: 33221342.
      45. Tang Z, Chen H, Hong L, Tang G, Toruner GA, Wang W, Roy Chowdhuri S, Yin W, Jung HS, Gu J, Routbort MJ, Zhang J, Khoury JD, Medeiros LJ. Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32674491.
      46. Geiersbach KB, Chen H, Emmadi R, Haskell GT, Lu X, Liu YJ, Swisshelm K. Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group. Cancer Genet 244:11-20, 2020. e-Pub 2020. PMID: 32087595.
      47. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res 22(1):69, 2020. e-Pub 2020. PMID: 32576238.
      48. Gu J, Tang Z, Chen H, Sfamenos S, Geiersbach KB. HER2 FISH for Breast Cancer: Advances in Quantitative Image Analysis and Automation. OBM Genetics 4(2), 2020. e-Pub 2020.
      49. Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One 15(11):e0241775, 2020. e-Pub 2020. PMID: 33180796.
      50. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol 92:32-38, 2019. e-Pub 2019. PMID: 31351155.
      51. Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Chen W, Iafrate AJ, Chi AS, Zagzag D, Golfinos JG, Placantonakis DG, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors. Neuro Oncol 21(9):1164-1174, 2019. e-Pub 2019. PMID: 31140557.
      52. Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova A. Challenges in Next Generation Sequencing Analysis of Somatic Mutations in Transplant Patients. Cancer Genet 226-227:17-22, 2018. e-Pub 2018. PMID: 30005850.
      53. Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol 35:69-76, 2018. e-Pub 2018. PMID: 29843069.
      54. Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17(7):1575-84, 2018. e-Pub 2018. PMID: 29695638.
      55. Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Coexistent Genetic Alterations Involving ALK, RET, ROS1 or MET in 15 Cases of Non-Small Cell Lung Cancer. Mod Pathol 31(2):307-312, 2018. e-Pub 2018. PMID: 28914263.
      56. Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET Amplification Assessed Using Optimized FISH Reporting Criteria Predicts Early Distant Metastasis in Patients with Non-Small Cell Lung Cancer. Oncotarget 9(16):12959-12970, 2018. e-Pub 2018. PMID: 29560123.
      57. Haskell GT, Liu YJ, Chen H, Chen B, Meyer RG, Yuhas JA, Geiersbach KB. Integrated Analysis of HER2 Copy Number by Cytogenomic Microarray in Breast Cancers with Non-Classical In Situ Hybridization Results. Am J Clin Pathol 149(2):135-147, 2018. e-Pub 2018. PMID: 29385416.
      58. Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RR. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet 212-213:24-31, 2017. e-Pub 2017. PMID: 28449808.
      59. Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra R. Concurrent Fine Needle Aspirations and Core Needle Biopsies: A Comparative Study of Substrates for Next-Generation Sequencing in Solid Organ Malignancies. Mod Pathol 30(4):499-508, 2017. e-Pub 2017. PMID: 28084342.
      60. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
      61. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn 18(5):676-687, 2016. e-Pub 2016. PMID: 27392636.
      62. Goswami RS, Luthra R, Singh RR, Singh RR, Patel KP, Patel KP, Routbort MJ, Routbort MJ, Aldape KD, Aldape KD, Yao H, Yao H, Dang HD, Dang HD, Barkoh BA, Barkoh BA, Manekia J, Manekia J, Medeiros LJ, Medeiros LJ, Roy-Chowdhuri S, Roy-Chowdhuri S, Stewart J, Stewart J, Broaddus RR, Broaddus RR, Chen H. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol 145(2):222-237, 2016. e-Pub 2016. PMID: 27124905.
      63. Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors Affecting the Success of Next-Generation Sequencing in Cytology Specimens. Cancer Cytopathol 123(11):659-668, 2015. e-Pub 2015. PMID: 26230354.
      64. Bousamra A, Chen H, Luthra R, Lu X, Aldape KD, Singh RR, Lu G, Abraham R, Virani S, Robinson M, Mishra BM, Sahin A. Molecular Inversion Probe Technology Generates High-quality HER2 Copy Number Data in Formalin-fixed Paraffin-embedded Breast Cancer. Journal of Cancer and Clinical Oncology, 2015. e-Pub 2015.
      65. Baker M, Chen H, Latchaw L, Memoli V, Ornvold K. Pseudoangiomatous Stromal Hyperplasia of the Breast in a 10-year-old Girl. J Pediatr Surg 46(46(8)):e27-31, 2011. e-Pub 2011. PMID: 21843705.
      66. Chen H, Lefferts JA, Schwab MC, Suriawinata AA, Tsongalis GJ. Correlation of polypoid colorectal adenocarcinoma with preexisting adenomatous polyps and KRAS mutation. Cancer Genet 204(204(5)):245-251, 2011. e-Pub 2011. PMID: 21665177.
      67. Chen H, Gonzalez JL, Brennick JB, Liu M, Yan S. Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A. Am J Surg Pathol 34(9):1250-7, 2010. e-Pub 2010. PMID: 20697251.
      68. Algoe KK, Chen H, Schned AR, Whiteside JL. Intraperitoneal India ink deposits appearing as endometriosis in a patient with chronic pelvic pain. Obstet Gynecol 112(112(2 Pt 2)):448-450, 2008. e-Pub 2008. PMID: 18669759.
      69. Chen H, Choudhury DM, Craig SW. Coincidence of actin filaments and talin is required to activate vinculin. J Biol Chem 281(281(52)):40389-40398, 2006. e-Pub 2006. PMID: 17074767.
      70. Bernstein BW, Chen H, Boyle JA, Bamburg JR. Formation of actin-ADF/cofilin rods transiently retards decline of mitochondrial potential and ATP in stressed neurons. Am J Physiol Cell Physiol 291(291(5)):C828-C839, 2006. e-Pub 2006. PMID: 16738008.
      71. Cohen DM, Kutscher B, Chen H, Murphy DB, Craig SW. A conformational switch in vinculin drives formation and dynamics of a talin-vinculin complex at focal adhesions. J Biol Chem 281(281):16006-16015, 2006. e-Pub 2006. PMID: 16608855.
      72. Chen H, Cohen DM, Choudhury DM, Kioka N, Craig SW. Spatial distribution and functional significance of activated vinculin in living cells. J Cell Biol 169(169(3)):459-470, 2005. e-Pub 2005. PMID: 15883197.
      73. Cohen DM, Chen H, Johnson RP, Choudhury B, Craig SW. Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin. J Biol Chem 280(280(17)):17109-17117, 2005. e-Pub 2005. PMID: 15728584.
      74. Chen H, Bernstein BW, Sneider JM, Boyle JA, Minamide LS, Bamburg JR. In vitro activity differences between proteins of the ADF/cofilin family define two distinct subgroups. Biochemistry 43(43):7127-7142, 2004. e-Pub 2004. PMID: 15170350.
      75. Okada K, Blanchoin L, Abe H, Chen H, Pollard TD, Bamburg JR. Xenopus actin interacting protein 1 (XAip1) enhances cofilin fragmentation of filaments by capping filament ends. J Biol Chem 277(277 (45)):43011-43016, 2002. e-Pub 2002. PMID: 12055192.
      76. Boyle JA, Chen H, Bamburg JR. Sperm incorporation in Xenopus laevis: Characterization of morphological events and the role of microfilaments. Zygote(9):167-181, 2001. e-Pub 2001.
      77. Bernstein BW, Painter WB, Chen H, Minamide LS, Abe H, Bamburg JR. Intracellular pH modulation of ADF/Cofilin proteins. Cell Motil Cytoskeleton 47(47(4)):319-336, 2000. e-Pub 2000. PMID: 11093252.
      78. Wang S, Bian Q, Liu Z, Feng Y, Lian N, Chen H, Hu C, Dong Y, Cai. Capability of serum to convert streptomycin to cytotoxin in patients with aminoglycoside-induced hearing loss. Hear Res 137(137):1-7, 1999. e-Pub 1999. PMID: 10545628.

      Invited Articles

      1. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel) 7(4):2023-2036, 2015. e-Pub 2015. PMID: 26473927.
      2. Chen H, Luthra R, Goswami RS, Singh RR, Roy-Chowdhuri S. Analysis of Pre-analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel) 7(3):1699-1715, 2015. e-Pub 2015. PMID: 26343728.
      3. Craig SW, Chen H. Lamellipodia protrusion: moving interactions of vinculin and Arp2/3. Curr Biol 13(13):R236-R238, 2003. e-Pub 2003. PMID: 12646151.
      4. Chen H, Bernstein BW, Bamburg JR. Regulating actin filament dynamics in vivo. Trends Biochem Sci 25(25):19-23, 2000. e-Pub 2000. PMID: 10637608.

      Review Articles

      1. Zheng, L, He, LJ, Chen, H, Ding, Q, Bishop, J, Peng, Y. CIC-rearranged sarcoma in the breast. Human Pathology 162, 2025. e-Pub 2025. PMID: 40398821.
      2. Sahin, AA, Chen, H, Xiao, H, Damodaran, S, Meric-Bernstam, F. Emerging molecular Therapeutic targets in breast Cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40759284.

      Professional Educational Materials

      1. Chen H, Seifi M. Secretory Carcinoma, 2024.
      2. Chen H, Hodge J. Acute Leukemias of Ambiguous Lineage, 2018.
      3. Chen H, Tang Y. HIV Serology testing. Clinical Chemistry Trainee Council Webcasts and Pearls of Laboratory Medicine, 2014.

      Other Articles

      1. Zhang Q, Zheng L, Chen H, Roy-Chowdhuri S, Hansel DH, Czerniak BA, Guo CC Mutational Profile of Small Cell Carcinoma of the Urinary Bladder. Lab Invest 104(3):S1088-S1089, 2024.

      Abstracts

      1. Ibrahim EE, Yang RK, Nagarajan P, Sweeney KJ, Chen H, Roy-Chowdhuri S, Lenskaya V, Aung PP, Curry JL, Ivan D, Prieto VG, Torres-Cabala CA, Cho WC. Clinicopathologic and Molecular Characterization of BRAF-Fused Melanomas: A Retrospective Analysis of 9 Cases with 8 Novel Fusions Detected by Next-Generation Sequencing 105(3), 2025. e-Pub 2025.
      2. Guerrouahen BS, Shah KP, Luthra R, Duose DY, Mantha GS, Piya S, Veliyathu JJ, Reddy NG, Luu SL, Famobio TB, Walters K, Alvarez H, Meric-Bernstam F, Patel KP, Roy-Chowdhuri S, San Lucas FA, Chen H. Optimizing Pre-Analytic Tissue Handling and RNA Extraction to Enhance RNA Expression Profiling of Solid Tumors in a CLIA Setting. J Mol Diagn 26(11):S161-S161, 2024. e-Pub 2024.
      3. Albarracin C, Wu Y, Sneige N, Chen H, Bedrosian I. A comparative analysis of WHO and MD Anderson classification of tumors: Impact on patient outcomes. Virchows Arch 485:S187-S187, 2024. e-Pub 2024.
      4. Albarracin C, Bedrosian I, Chen H, Wu Y. Multidisciplinary approach in stratifying risk of upgrade and tailoring management in ADH patients. Virchows Arch 485:S51-S51, 2024. e-Pub 2024.
      5. Shen Y, Zheng L, Zhao J, Wang Y, Chen H, Wei P, Roy-Chowdhuri S, Hansel DH, Czerniak BA, Guo CC. Molecular Profile of Micropapillary Urothelial Carcinoma of the Urinary Bladder: An Analysis of 99 Cases by Next Generation Sequencing. Lab Invest 104(3):S1054-S1055, 2024. e-Pub 2024.
      6. Al-Attar M, Elzamly S, Zhang Q, Zheng L, Chen H, Roy-Chowdhuri S, Hansel DH, Czerniak BA, Guo CC. Mutational Profile of Sarcomatoid Urothelial Carcinoma. Lab Invest 104(3):S898-S899, 2024. e-Pub 2024.
      7. Sun H, Huo L, Sweeney KJ, Resetkova E, Chai D, Chen H, Albarracin CT, Wu Y, Ding Q. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study. Lab Invest 104(3):S274-S275, 2024. e-Pub 2024.
      8. Ye Q, Klippel D, Albarracin CT, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton LP, Resetkova E, Sahin A, Sun H, Sweeney KJ, Symmans WF, Wu Y, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Lab Invest 104(3):S321-S322, 2024. e-Pub 2024.
      9. Sun BH, Guerrouahen B, Piya S, Duose D, Umzunparmak B, Reddy N, Famobio T, Veliyathu JJ, Luu S, Walters K, Ninan S, Meric-Bernstam F, Luthra R, Roy-Chowdhuri S, Wang W L, Wistuba I, Mantha G, Chen H. TROP2 Immunohistochemical Assay in Solid Tumors: Comparison of Interpretation Scoring Assessments by H-Score and Clinical Trials Driven ADC-Score. Lab Invest 104(3):S1800-S1801, 2024. e-Pub 2024.
      10. Goetz L, Ye Q, Sneige N, Wu Y, Bedrosian I, Chen H, Albarracin C. Histologic Review of Phyllodes Tumors: A Comparative Review with Patient Outcomes. Lab Invest 104(3):S164-S165, 2024. e-Pub 2024.
      11. Guerrouhen BS, Piya S, Alvarez H, Dzifa D, Luthra RL, Reddy N, Uzunparmak B, Famobio T, Walters K, Luu S, Villanueva A, Veliyathu J, NguyenA, Patel KS, Tran DK, ViraniK, Roy-Chowdhuri S, Mantha G, Chen H. Optimization of Fixed Solid Tumor Sample Preparation in RNase free Environment for RNA-based CLIA Assays. J Mol Diagn 25(11):S149-S149, 2023. e-Pub 2023.
      12. Lucas FS, Alvarez H, Pelicano H, Gascoyne J, Cason R, Palmer A, Decebal-Rojas J, Mercado J, Chen S, Shah KP, Reddy N, Ninan S, Ozenci J, Duose D, Floyd K, Ballester L, Chen H, Kanagal R, MacAndrew W, Yang R, Patel KP, Routbort M, Roy S, Wistuba I, Hansel D, Luthra R, Medeiros J. Revolutionizing Genetic Testing for Tissue and Liquid Biopsies: Automating and Simplifying Next-Generation Sequencing Workflows at MD Anderson Cancer Center. J Mol Diagn 25(11):S13-S13, 2023. e-Pub 2023.
      13. Piya S, Nguyen A, Patel KS, Dzifa Duose D, Reddy N, Veliyathu J, Baltaji M, Tran DK, Virani K, Famobio T, Walters K, Guerrouahen B, Chen H, Luu S, Manyam G, Mantha G, Kopetz S, Morris JS, Maru DM, Alvarez H, Luthra RL. Development and Analytical Validation of nCounter-Platform Assay to Stratify Colorectal Cancer (CRC) into Consensus Molecular Subtype. J Mol Diagn 25(11):S148-S148, 2023. e-Pub 2023.
      14. Roy-Chowdhuri S, Chen H, San Lucas FA, Alvarez HA, Dang HD, Duose DY, Rashid A, Routbort MJ, Patel KP, Yang RK, Ballester LY, Sweeney K, Toruner G, Luthra R. Comparison of DNA-Based and RNA-Based Next-Generation Sequencing for the Detection of MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer. J Mol Diagn 25(11):S106-S107, 2023. e-Pub 2023.
      15. Alvarez HA, San Lucas FA, Luthra R, Rashid A, Dang HD, Duose DY, Routbort MJ, Patel KP, Yang RK, Ballester LY, Toruner G, Sweeney K, Roy-Chowdhuri S, Chen H. Comparison of Microsatellite Instability Assays by Conventional PCR and Next Generation Sequencing. J Mol Diagn 25(11):S104-S104, 2023. e-Pub 2023.
      16. San Lucas FA, Daniel Wang D, Olvera-Morales AL, Puthooran S, Roy-Chowdhuri S, Chen H, Sweeney K, Yang RK, Toruner G, Patel KP, Routbort MJ, Luthra R, Scheet PA, Alvarez HA, Ballester LY. Diagnosis of Oligodendroglioma IDH-Mutant and 1p/19q-Codeleted Using Targeted NGS. J Mol Diagn 25(11):S112-S112, 2023. e-Pub 2023.
      17. Wu Y, Mersereau M, Chen H, Albarracin C. Ki67 Quantitation in Breast Cancer: A Comparative Analysis of Four Counting Methods, 2023. e-Pub 2023.
      18. Diks J, Tang ZY, Altan M, Chen H, Rashid A, Yang R, Routbort M, Patel K, Toruner G, Tang GL, Roy-Chowdhuri S. Clinically Actionable Gene Fusion Detection by Next-Generation Sequencing-Based RNA Sequencing in Non-Small Cell Lung Cancer Cytology Specimens: A Single Center Experience with Comparison to Fluorescence in Situ Hybridization. Lab Invest 103(3):S291-S292, 2023. e-Pub 2023.
      19. Zheng L, Luthra R, Liu A, Fuller G, San Lucas F, Roy-Chowdhuri S, Sweeney K, Chen W, Alvarez H, Rashid A, Yang R, Ballester L, Patel K, Routbort M, Sahin A, Ding QQ, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4,331 Solid Tumors. Lab Invest 103(3):S1576-S1577, 2023. e-Pub 2023.
      20. Zheng L, Chen H, Zhao JP, Czerniak B, Roy-Chowdhuri S, Guo C. Mutational Landscape of Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: An Analysis of 51 cases by Next Generation Sequencing. Lab Invest 103(3):S839-S840, 2023. e-Pub 2023.
      21. Chen H, Wu Y, Ding Q, Huo L, Khazai L, Sahin AA, Albarracin CT. HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX. Lab Invest 103(3):S114-S114, 2023. e-Pub 2023.
      22. Salem A, Han C, Wu Y, Albarracin CT, Middleton LM, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Acinic Cell, and Secretory Carcinomas of the Breast and Salivary Glands. Lab Invest 103(3):S206-S207, 2023. e-Pub 2023.
      23. E-Y K, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding Q, Foo WC, Sahin AA. Immunohistochemical Assessment of HER2-Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis. Lab Invest 103(3):S1720-S1720, 2023. e-Pub 2023.
      24. Minussi DC, Wang J, Schalck A, Yan Y, Wu HJ, Peng C, Hu M, Sei E, Edgerton M, Chen H, Contreras A, Hui D, Damodaran S, Kopetz S, Lim B, Navin N. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit. Cancer Research 82(12), 2022. e-Pub 2022.
      25. Salem A, Chen H, Albarracin C, Wu Y, Sneige N, Khazai L, Ding QQ, Tang ZY, Sahin A, Yoon E. Correlation amongst Immunohistochemical (IHC) Scores, Fluorescence In Situ Hybridization (FISH) Groups and Final HER2 Status on Breast carcinoma (BC) and Quality Issues Surrounding Indeterminate FISH Tests: A Single Center Experience. Mod Pathol 35(Suppl 2):1384-1385, 2022. e-Pub 2022.
      26. Yoon E, Wang G, Wu Y, Chen H, Albarracin C, Resetkova E, Krishnamurthy S, Salisbury T, Sahin A, Ding QQ. Expression of TRPS1, SOX10 and GATA3 in Triple Negative Invasive Ductal and Lobular Carcinomas. Mod Pathol 35(Suppl 2):216-217, 2022. e-Pub 2022.
      27. Sweeney K, Wang J, Albarracin C, Roy-Chowdhuri S, Patel K, Routbort M, Ding Q, Wu Y, Huo L, Sahin A, Luthra R, Chen H. PTEN Alterations in Advanced ER plus Breast Cancer: Correlation with Clinicopathologic and Molecular Features. Mod Pathol 35(Suppl 2):198-199, 2022. e-Pub 2022.
      28. Ai D, Sweeny KJ, Chen H, Huo L, Wu Y, Resetkova E, Yoon EC, Wang WL, Albarracin CT. ER-/PR+ Breast Cancer Cases Across Two FDA-Approved Platforms: Incidence and Clinicopathologic Correlates. Lab Invest 101(Suppl 1):1140-1141, 2021. e-Pub 2021.
      29. Wang J, Albarracin CT, Huo L, Ding Q, Wu Y, Roy-Chowdhuri S, Patel KP, Routbort M, Luthra R, Chen H. PTEN Alteration in ER+ Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing. Mod Pathol 34(Suppl 2):161, 2021. e-Pub 2021.
      30. Zaleski MP, Chen H, Czerniak BA, Guo CC. Next-Generation Sequencing Analyses of Gene Mutations in Urachal Carcinoma. Mod Pathol 34(Suppl 2):636-637, 2021. e-Pub 2021.
      31. Bose PS, Ding X, Batra H, Chen H, Wu Y, Rosa MG, Sahin A, Wistuba II, Ding Q, Yang F. MYB Expression by Immunohistochemistry is Highly Specific and Sensitive for Detection of Solid Variant of Adenoid Cystic Carcinoma of the Breast, amidst all Triple Negative Breast Cancers. Mod Pathol 34(Suppl 2):153-154, 2021. e-Pub 2021.
      32. Nezami BG, Toruner GA, Routbort M, San Lucas F, Yang RK, Seyedjafari R, Chen H, Rashid A, Loghavi S, Roy-Chowdhuri S, Kanagal-Shamanna R, Yin CC, Zuo Z, Ok CY, Tang Z, Medeiros JL, Luthra R, Patel KP. Clinical Utility of NGS-Based Gene Fusion Testing in Solid Tumors. Lab Invest 101(Suppl 1):513-514, 2021. e-Pub 2021.
      33. Minussi DC, Nicholson M, Ye HH, Davis A, Wang KL, Sei E, Du HW, Rabbani M, Peng C, Hu M, Bai SS, McDonald T, Schalck A, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Michor F, Navin N. Breast tumors maintain a reservoir of subclonal diversity during primary expansion. Cancer Research 80(21), 2020. e-Pub 2020.
      34. Kumar T, Nguyen Q, Nee, K, Bai SS Hu M, Sei E, Wood A, Wiley J, Chen H, Contreras A, Teshome M, Chen K, Lim B, Lawson D, Navin N, Kessenbrock K. A spatially resolved single cell atlas of the human breast. Cancer Research 80(16), 2020. e-Pub 2020.
      35. Chen H, Hou T, Huo L, Wu Y, Wang WL, Albarracin CT. Significance of ER-/PR+ Breast Cancer Cases: Re-evaluating of Biomarker Studies and Clinical Correlates. Lab Invest 100(Suppl 1):1848-1848, 2020. e-Pub 2020.
      36. Ramani N, Routbort M, Patel KP, Broaddus R, Chen H, Rashid A, Lazar AJ, Medeiros LJ, Manekia J, Dang H, Luthra R, Stewart J, Roy-Chowdhuri S. Utilization of Cytology Smears for NGS-Based RNA Fusion Testing Improves Adequacy Rates. Modern Pathology 33:408-409, 2020. e-Pub 2020.
      37. Ramani N, Routbort M, Patel KP, Yao H, Broaddus R, Chen H, Rashid A, Lazar AJ, Manekia J, Dang H, Mantha G, Medeiros LJ, Luthra R, Roy-Chowdhuri S. Factors Affecting the Success of Clinically Relevant RNA Fusion Assays Using Next Generation Sequencing. Lab Invest 100(Suppl 1):1891-1892, 2020. e-Pub 2020.
      38. Wang J, Chen H, Koenig J, Bedrosian I, Wu Y, Albarracin C. Discordance of Oncotype DX Scores in Bilateral and Unilateral Multifocal Breast Cancers. Mod Pathol 33(Suppl 2):279-280, 2020. e-Pub 2020.
      39. Huang X, Ding Q, Guo H, Sui D, Gong Y, Wu Y, Chen H, Wang WL, Huo L. Comparison of Three FDA Approved PD-L1 Immunohistochemistry Assays in Triple Negative Breast Carcinoma. Mod Pathol 33(Suppl 2):182-184, 2020. e-Pub 2020.
      40. Huang X, Chen H, Ding Q, Robinson MK, Bassett RL, Tang G, Sahin A. Clinicopathological Features of HER2 Positive Classic Invasive Lobular Carcinoma. Mod Pathol 33(Suppl 2):180-182, 2020. e-Pub 2020.
      41. Chen H, Wang MH, Sun HX, Gu J, Tang ZY, Tang GL, Sfamenos S, Robinson M, Sahin A. Breast cancer with HER2 FISH test result in group 2: Should HER2 test be repeated?. Cancer Research 80(4), 2020. e-Pub 2020.
      42. Crespo J, Sun HX Wu JM, Ding QQ, Tang GL, Robinson M, Chen H, Sahin AA, Lim B. HER2 targeted therapy and outcome in HER2equivocal cases after 2018 ASCO/CAP HER2 guideline modification. Journal of Clinical Oncology 37(15), 2019. e-Pub 2019.
      43. Wang P, Luthra R, Routbort MJ, Chen H, Loghavi S, OK CY, Alvarez H, Yang R, Broaddus R, Mantha G, Hamilton SR, Medeiros JL, Patel KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Ultrasensitive and Minimally Invasive Detection of Genomic Variants with a Faster Turnaround Time. Modern Pathology 32, 2019. e-Pub 2019.
      44. Seth TK, Bai S, Hu M, Sei E, Wood A, Wiley J, Chen H, Contreras A, Teshome M, Lim B, Navin NE. Towards a human breast cell atlas. Cancer Research 79(4), 2019. e-Pub 2019.
      45. Sun H, Chen H, Lim B, Sahin AA. Clinical and pathological features of breast cancer with 'polysomy' of Chromosome 17. Cancer Research 79(4), 2019. e-Pub 2019.
      46. McLemore LE, Albarracin C, Gruschkus SK, Dhamne S, Basset Jr S, Wu Y, Yim I, Lin K, Chen H. HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO-CAP 2013 with 2018 Guidelines. Mod Pathol, 2019. e-Pub 2019.
      47. Ding Q, Sun H, Lim B, Aranibar Crespo J, Tang G, Robinson M, Sahin A, Chen H. Retrospective Analysis of 158 Breast Cancer Cases of Group 4 HER2 FISH. Mod Pathol, 2019. e-Pub 2019.
      48. McLemore LE, Chen H, Dhamne S, Basset Jr S, Gruschkus SK, Wu Y, Yim I, Lin K, Albarracin C. Estrogen receptor immunohistochemical staining versus Oncotype DX: Clinicopathologic characteristics and recurrence scores of concordant and discordant cases. Mod Pathol, 2019. e-Pub 2019.
      49. Abbott SE, Broaddus R, Routbort MJ, Roy-Chowdhuri S, Yemelyanova A, Rashid A, Luthra R, Patel KP, Chen H. Next-Generation Sequencing for the Detection of Actionable Genetic Alternations in Advanced Breast Cancer: Should We Be Testing and How?. Journal of Molecular Diagnostics 20(6):1002, 2018. e-Pub 2018.
      50. Liu C, Chen H, Fang L, Hu PC, Gu J, Zhao J, Abraham R, Yao H, Singh RR, Medeiros LJ, Luthra R, Lu X. Genomic profiling of lung adenocarcinomas with increased MET copy numbers. Cancer Genetics 226-227:51, 2018. e-Pub 2018.
      51. Hodge JC, Cooley L, Chen H, Yang F, Pitel B, Sathanoori M, Davis B, Corboy G, Griffith O, Baughn L, Newman S, Wolff D. Progress and future of the Compendium of Cancer Genome Aberrations (CCGA). Cancer Genetics 226-227:37-38, 2018. e-Pub 2018.
      52. Geiersbach K, Liu YJ, Haskell GT, Chen H, Lu X, Swisshelm K, Emmadi R, Fang M. Current Concepts in Breast Cancer Genomics: An Evidence Based Review from the Cancer Genomics Consortium (CGC) Breast CAncer Workgroup. Cancer Genetics 226-227:43-44, 2018. e-Pub 2018.
      53. Chen H, Routbort M, Yemelyanova Y, Patel KP, Manekia J, Broaddus R, Luthra R. Multiplex Paired Tumor-Normal Sequencing Analysis with Discordant Sequence-based Patient Identifiers in Stem Cell Transplant Patients. Cancer Genetics 226-227:55-56, 2018. e-Pub 2018.
      54. Abbott SE, Broaddus R, Huo L, Albarracin C, Routbort MJ, Luthra R, Patel KP, Chen H. ESR1 Somatic Mutation Analysis in Advanced Breast Cancer: Correlation with Clinicopathologic and Molecular Features 31(Suppl. 2):42-42, 2018. e-Pub 2018.
      55. Albarracin C, Trinidd CM, Song J, Ward K, Dhamne S, Rosen D, Wu Y, Chen H, Baghaki HS, Barrera AMG, Arun B. Androgen Receptor Expression In BRCA-Associated Breast Cancers 31(Suppl. 2):44-44, 2018. e-Pub 2018.
      56. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder S, Wang W, Huo L. PD-L1 Expression (clone 28-8) and Tumor Infiltrating Lymphocytes (TIL) in Primary Breast Cancer 31(Suppl. 2):65-66, 2018. e-Pub 2018.
      57. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder S, Wang W, Huo L. PD-L1 Expression (clone 22C3) and Tumor Infiltrating Lymphocytes (TIL) in Primary Breast Cancer 31(Suppl. 2):65-65, 2018. e-Pub 2018.
      58. Chang N, Chen H, Al-Awadhi A, Lim B, Robinson M, Tang G, Sahin A. Equivocal HER2/neu FISH Results in Breast Cancer: How Frequently Do They Change on Repeat Testing? 31(Suppl. 2):53-53, 2018. e-Pub 2018.
      59. Abbott SE, Broaddus R, Chen H. The Landscape of Somatic Mutations in Advanced Breast Cancer: A Unique Population with Comparison to Public Studies 31(Suppl. 2):695-695, 2018. e-Pub 2018.
      60. Abbott SE, Broaddus R, Chen H. Actionable Genetic Alterations in Advanced Breast Cancer: A Frequency Analysis by Molecular Subtype 31(Suppl.2):42-42, 2018. e-Pub 2018.
      61. Yemelyanova A, Routbort M, Broaddus R, Chen H, Rashid A, Roy-Chowdhuri S, Lazar A, Manekia J, Mohammad M, Mantha G, Singh R, Luthra R, Hamilton S, Medeiros LJ, Patel KP. Tumor in Normal or Normal in Tumor: What to Do When Somatic Mutations Are Detected in “Normal” Germline Control Used for NGS-Based Targeted Somatic Mutation Testing. The Journal of Molecular Diagnostics 19(6):1027, 2017. e-Pub 2017.
      62. Fang L, Lu X, Hu X, Tang Z, Luthra R, Routbort M, Patel K, Wang R, Broaddus R, Chen H. MET Amplification Predicts Primary Resistance to EGFR-TKIs in Advanced Non–Small Cell Lung Cancer Patients with Sensitive EGFR Mutation. The Journal of Molecular Diagnostics 19(6):1032, 2017. e-Pub 2017.
      63. Zhao J, Lu X, Zhang M, Guo C, Huo L, Yemelyanova A, Navai N, Broaddus R, Chen H. Integration of HER2 Overexpression/amplification with Molecular Mutation Profile in Urothelial Carcinoma. The Journal of Molecular Diagnostics 19(6):1032, 2017. e-Pub 2017.
      64. Chen H, Sahin AA, Lu X, Huo L, Singh RR, Abraham R, Virani S, Mishra BM, Broaddus R, Luthra R. Assessment of breast cancer with borderline HER2 status using MIP microarray. Cancer Genetics. Cancer Genetics 214-215:39, 2017. e-Pub 2017.
      65. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul SA, Luthra R, Broaddus RR, Meric-Bernstam F, Sahin AA. HER2 Somatic Mutation Analysis in Breast Cancer: Correlation with Clinicopathologic Features 30(Suppl. 2):39a-39a, 2017. e-Pub 2017.
      66. Dogan S, Benayed R, Chen H, Arcila ME, Berger MF, Katabi N. Genomic Profiling of the Two Closely Related "cousins" Acinic Cell Carcinoma and Mammary Analog Secretory Carcinoma of Salivary Glands Reveals Novel NCOA4-RET Fusion in Mammary Analog Secretory Carcinoma 30(Suppl. 2):323a-323a, 2017. e-Pub 2017.
      67. Fang L, Chen H, Medeiros LJ, Hu S, Lin P, Luthra R, Singh RR, Routbort MJ, Hong D, Lu X. Correlation between MET Gene Copy Number and Molecular Profiling in Non-Small Cell Lung Cancer 30(Suppl. 2):478a-478a, 2017. e-Pub 2017.
      68. Fang L, Chen H, Medeiros LJ, Hu S, Lin P, Luthra R, Singh RR, Routbort MJ, Hong D, Lu X. Optimization of MET FISH Reporting Criteria in Non-Small Cell Lung Cancer: MD Anderson Experience 30(Suppl. 2):507a-507a, 2017. e-Pub 2017.
      69. Roy-Chowdhuri R, Routbort M, Singh RR, Broaddus R, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Manekia J, Chen W, Medeiros JL, Hamilton S, Luthra R, Patel KP. SNP Signature-Based Sample Identification As a Patient Safety Tool in NGS-Based Targeted Oncologic Testing. The Journal of Molecular Diagnostics 18(6):1049, 2016. e-Pub 2016.
      70. Chen H, Routbort M, Rashid A, Roy-Chowdhuri S, Patel KP, Lazar A, Broaddus R, Manekia J, Singh RR, Luthra R, Yemelyanova A. Challenges in Next Generation Sequencing Analysis of Somatic Mutations in Transplant Patients. The Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
      71. Lee SM, Broaddus RR, Pattanaprichakul P, Udompunturak S, Singh RR, Routbort M, Patel KP, Luthra R, Rashid A, Chen H. Molecular Characterization of Appendiceal Mucinous Neoplasms: Stratification of KRAS, GNAS, and TP53 Mutations by Tumor Grade. The Journal of Molecular Diagnostics 18(6):1001, 2016. e-Pub 2016.
      72. Olar A, Broaddus R, RoutbortM, Roy-Chowdhuri S, Hodges KB, Singh RR, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Medeiros JL, Hamilton SR, Luthra R, Pathel KP. Value of Paired Tumor-Normal Analysis in Solid Tumor Genotyping by Next-Generation Sequencing. The Journal of Molecular Diagnostics 18(6):1005, 2016. e-Pub 2016.
      73. Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Iafrate AJ, Golfinos J, Chi A, Zagzag D, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. The Prognostic Value of Polysomy in Oligodendroglial Tumors 18(suppl_6):vi113, 2016. e-Pub 2016.
      74. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu XY, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. Journal of Molecular Diagnostics 18(5):676-687, 2016. e-Pub 2016.
      75. Chen H, Bousamra A, Luthra R, Lu X, Aldape KD, Singh RR, Abraham R, Virani S, Mishra BM, Sahin SA. Her2 Assessment by MIP Microarray in a Breast Cancer Patient with Equivocal Her2 Status. Cancer Genetics 209, 2016. e-Pub 2016.
      76. Salim AA, Luthra R, Singh R, Patel KP, Routbort MJ, Barkoh BA, Manekia J, Roy-Chowdhuri S, Broaddus RR, Chen H. Pre-Analytical Factors Involved in the Clinical Analysis of a Comprehensive Next-Generation Sequencing Panel. Modern Pathology 29:504a, 2016. e-Pub 2016.
      77. Albarracin C, Dhamn, S, Arun, Ward K, Wu Y, Rosen D, Cui XY, Resetkova E, Duan XZ, Chen H, Bedrosian I, Barrera AG. BRCA1 and BRCA2-Associated Breast Cancers Demonstrate Distinct Histopathologic Features, Biomarker Expression Patterns and Molecular Subtypes. Modern Pathology 29:39a-39a, 2016. e-Pub 2016.
      78. Chen H, Broaddus R, Barkoh B, Abraham R, Singh R, Luthra R, Roy-Chowdhuri S. Evaluating Pathologist Accuracy in Estimation of Percentage of Malignant Cells. Modern Pathology 29:492a, 2016. e-Pub 2016.
      79. Roy-Chowdhuri S, Chen H, Staerkel G, Stewart J. Morphologic Assessment of Cytology Fine Needle Aspiration and Concurrent Surgical Core Needle Biopsy for Molecular Analysis: Comparing Overall Cellularity and Tumor Fraction. Modern Pathology 29:114a, 2016. e-Pub 2016.
      80. Lee SM, Broaddus R, Singh R, Luthra R, Chen H. Mutation Profile of Colorectal Neuroendocrine Neoplasm. Modern Pathology 29:182a, 2016. e-Pub 2016.
      81. Ok C, Loghavi S, Salim SS, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broadus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros BL, Singh RR, Routbort MJ, Luthra R, Patel KP. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. The Journal of Molecular Diagnostics 17(6):810, 2015. e-Pub 2015.
      82. Lui C, Chen H, Hu PC, Abraham R, Robinson MK, Yao H, Singh RR, Luthra R, Lu X. Characterization of MET Amplification in Lung Adenocarcinomas Using OncoScan SNP Microarray. The Journal of Molecular Diagnostics 17(6):822, 2015. e-Pub 2015.
      83. Chen H, Lu X, Singh R, Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort M, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative Assessment of ESR, PGR, and Genome-Wide Copy Number Aberrations in Advanced Breast Cancer by SNP Microarray. The Journal of Molecular Diagnostics 17(6):840, 2015. e-Pub 2015.
      84. Bousamra A, Chen H, Luthra R, Lu X, Aldape KD, Singh RR, Lu G, Abraham R, Virani S, Robinson M, Mishra BM, Sahin A. Assessing Tumor Percentage: A Possible Solution in Evaluating HER2 Copy Number (CN) Data Generated by Molecular Inversion Probe (MIP) Technology on Formalin-Fixed Paraffin Embedded (FFPE) Sections of Breast Cancer (BC) with Low Tumor Cellularity. American Journal of Clinical Pathology 144:A239, 2015. e-Pub 2015.
      85. Chen H, Luthra R, Kalhor N, Heymach J, Abraham R, Mehrotra M, Mishra BM, Patel KP, Singh RR, Lu X. Unusual ROS1 Translocation Pattern in a 61 Year-old Woman with Metastatic Adenocarcinoma of Lung. Cancer Genetics 208(6):363, 2015. e-Pub 2015.
      86. Bousamra A, Chen H, Luthra R, Lu X, Aldape K, Singh R, Lu G, Abraham R, Virani S, Mishara BM, Sahin A. Molecular Inversion Probe (MIP) Technology Generates High Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer 28(Suppl 2):511A, 2015. e-Pub 2015.
      87. Chowdhari SR, Goswami R, Chen H, Barkoh B, Mamekia J, Patel K, Routbort M, Singh R, Broaddus R, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors Affecting the Success of Next-Generation Sequencing in Cytology Specimens 28(Suppl 2):105A, 2015. e-Pub 2015.
      88. Goswami R, Chen H, Patel K, Routbort M, Yao H, Dang H, Barkoh B, Aldape K, Chowdhuri SR, Stewart J, Medeiros L, Broaddus R, Singh R, Luthra R. Inproving Next-Generation Sequencing (NGS) Success in Solid Tumors 28(Suppl 2):499A, 2015. e-Pub 2015.
      89. Chen H, Luthra R, Routbort M, Patel K, Singh R, Dang H, Barkoh B, Cabanillas M, Aldape K, Broaddus R, Williams M. Mutation Profile of Advance Thyroid Carcinomas by Next Generation Sequencing: The MDACC Experience 28(Suppl 2):322A, 2015. e-Pub 2015.
      90. Chen H, Singh R, Huo L, Lu X, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Chowdhuri SR, Routbort M, Aldape K, Broaddus R, Sahin A, Patel K, Luthra R. FGFR1 and EGFR Amplification in Breast Cancer 28(Suppl 2):38A, 2015. e-Pub 2015.
      91. Wang J, Zhou J, Patel T, Busam K, Chen H, Weigelt B, Ladanyi M, Hameed M, Wang L. Evaluation of the Affymetrix OncoScan Genome-Wide SNP-array Analysis Platform for Solid Tumor Molecular Diagnosis. J Mol Diagn 16(6):784, 2014. e-Pub 2014.
      92. Chen H, Broaddus R, Huo L, Zhang M, Guo C, Robinson M, Trivedi S, Fernandez R, Navai N, Lu X. Examination of HER2 overexpression and amplification in urothelial carcinoma with micropapillary features using ASCO/CAP 2013 guideline. J Mol Diagn 16(6):784, 2014. e-Pub 2014.
      93. Goswami RS, Luthra R, Patel KP, Routbort MJ, Singh RR, Dang HD, Barkoh BA, Yao H, Aldape KD, Broaddus RR, Chen H. Factors Affecting the Success of Next-Generation Sequencing Analysis in Solid Tumors. J Mol Diagn 16(6):778, 2014. e-Pub 2014.
      94. Singh RR, Abraham R, Mehrotra M, Patel KP, Roy Chowdhuri S, Chen H, Broaddus R, Routbort MJ, Wang X, Mishra BM, Aldape K, Luthra R. Validation of Molecular Inversion Probe-based Array for Detection of Copy Number Variations in Solid Organ Cancers using Formalin-fixed Paraffin Embedded Tissue. J Mol Diagn 16(6):770, 2014. e-Pub 2014.
      95. Chen H, Singh RR, Abraham R, Mehrotra M, Mishra BM, Roy-Chowdhuri S, Routbort M, Aldape K, Broaddus R, Patel KP, Luthra R. KRAS Amplification In A 73 Year-Old-Man With Adenocarcinoma Of Lung, 2014. e-Pub 2014.
      96. Goswami RS, Patel KP, Dang HD, Singh RR, Barkoh BA, Routbort MJ, Aldape KD, Hamilton SR, Broaddus RR, Luthra R, Chen H. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumour Tissue: Evaluation of 614 Clinical Cases. Canadian Association of Pathologists, 2014. e-Pub 2014.
      97. Chen H, Singh RR, Luthra R, Routbort M, Patel KP, Goswami RS, Abraham R, Dang H, Aldape K, Broaddus R. CSF1R amplification in poorly differentiated colorectal adenocarcinoma with neuroendocrine differentiation. J Mol Diagn 16(6):770, 2014. e-Pub 2014.
      98. Roy-Chowdhuri S, Goswami RS, Chen H, Routbort MJ, Patel KP, Aldape K, Lazar AJ, Broaddus R, Singh RR, Luthra R, Kanagal-Shamanna R. Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) Mutations in Solid Organ Malignancies by Next Generation Sequencing. J Mol Diagn 16(6):767, 2014. e-Pub 2014.
      99. Patel KP, Routbort M, Aldape K, Broaddus R, Lazar A, Roy Chowdhuri S, Rashid A, Singh R, Zuo Z, Chen H, Kanagal Shamanna R, Goswami RS, Jabbar K, BarkohBA, Manekia J, Luthra R. Development of a quality assurance framework for clinical interpretation and reporting of next-generation sequencing-based molecular oncology testing. J Mol Diagn 16(6):778, 2014. e-Pub 2014.
      100. H C, Comer S, Rosenblum M, Huse J, Wang L, Jhanwar S, Nafa K, Hameed MR. 1p /19q co-deletion and polysomy in oligodendroglial tumors- A single institution study. Modern Pathlology 26 (s2):415A, 2013. e-Pub 2013.
      101. Chen H, Chen YB, Gopalan A, Samson W Fine S, Hameed MR, Modak S, Reuter VE, Al-Ahmadie HA, Tickoo SK. ALK Point Mutations in Neuroblastoma: Association with Poorly Differentiated Morphology. Society for Pediatric Pathology, 2013. e-Pub 2013.
      102. Chen H, Nafa K, Borsu L, Hedvat CV, Sherman EJ, Ghossein RA, and Dogan S. Mutation Profile and Morphologic Spectrum of Advanced Thyroid Cancer: MSKCC Experience. J Mol Diagn 15(6):916, 2013. e-Pub 2013.
      103. Chen H, McClain D, Jhanwar SC, Agaram NP, Hameed MR. Complex Interphase Fluorescent in situ Hybridization Patterns of EWSR1 Gene in Ewing Sarcoma Using Break Apart Probes. Laboratory Investigation 92 (s1): 10A. Modern Pathology 25 (s2):10A, 2012. e-Pub 2012.
      104. McClain D, Chen H, Jhanwar S, Agaram N, Hameed M. Interphase fluorescent in situ hybridization patterns in translocation associated sarcomas. Laboratory Investigation 92 (s1): 17A. Modern Pathology 25 (s2):17A, 2012. e-Pub 2012.
      105. Lefferts JA, Chen H, Suriawinata AA, Tsongalis GJ. Targeted Screening of Colorectal Cancers for a Novel BUB1B Mutation. The Journal of Molecular Diagnostics, 2011. e-Pub 2011.
      106. Chen H, Yan S. A case of granular-cell basal cell carcinoma resembling sebaceous carcinoma. ASDP, 2010. e-Pub 2010.
      107. Kreuter JD, Chen H, Lee H. Comparison of Sweat Chloride by Macroduct and Gauze Collection Techniques. Archives of pathology & laboratory medicine(134 (9)):1373, 2010. e-Pub 2010.
      108. Lefferts JA, Chen H, Tafe LJ, Schwab MC, Suriawinata AA, Tsongalis GJ. Detection of BRAF V600E Mutations in Cases of Medullary Colorectal Cancer. Journal of molecular diagnostics 12(6):901 (ST23), 2010. e-Pub 2010.
      109. Chen H, Baker ML, Latchaw LA, Memoli VA, Ornvold KT. Pseudoangiomatous Stromal Hyperplasia of Breast in a 10-Year-Old Girl. Archives of pathology & laboratory medicine(134 (9)):1372, 2010. e-Pub 2010.
      110. Lefferts JA, Chen H, Suriawinata AA, Tsongalis GJ. Comparison of TaqMan PCR and Pyrosequencing Assays for Assessment of KRAS Mutations in FFPE Colorectal Cancer Specimens(90 suppl 1):435A, 2010. e-Pub 2010.
      111. Chen H, Lefferts J, Tsongalis GJ, Suriawinata AA. Correlation of KRAS Mutation and Villous Adenoma in Colorectal Adenocarcinoma Guides Pretreatment Screening and Targeted Therapy(90 suppl 1):140A, 2010. e-Pub 2010.
      112. Chen H, Klinker K, Hill J, Szczepiorkowski ZM. Passively acquired HBc and HTLV I/II antibodies from intravenous immunoglobulin therapy in a stem-cell transplant patient. Transfusion(49 3S):179A, 2009. e-Pub 2009.
      113. Chen H, Lefferts J, Tsongalis GJ, Suriawinata AA. Preexisting Villous Adenoma in Colorectal Adenocarcinoma Predicts the Status of KRAS Mutation in Targeted Therapy. Archives of pathology & laboratory medicine(133 (10)):1621, 2009. e-Pub 2009.
      114. Chen H, Yan S, Gonzalez J, Brennick J, Liu M. Immunohistochemical patterns of ProExC in vulvar squamous lesions. ASDP, 2008. e-Pub 2008.
      115. Chen H, Choudhury D, Craig SW. Vinculin is activated by coordinated action of talin and F-actin. Molecular biology of the cell(16 suppl):488a, 2005. e-Pub 2005.
      116. Chen H, Cohen DM, Choudhury BD, Craig SW. Spatial and temporal resolution of vinculin activation in cells. Molecular biology of the cell(15 suppl):85a, 2004. e-Pub 2004.
      117. Cohen DM, Kutscher B, Chen H, Murphy D, Craig SW. Mutagenesis of the head:tail interaction in vinculin reveals a role for conformational change in dynamics of vinculin and talin at focal adhesions. Molecular biology of the cell(15 suppl):81a-82a, 2004. e-Pub 2004.
      118. Chen H, Craig SW. Ligand-specific alterations of the structure of vinculin tail revealed by FRET. The FASEB Journal(17(5)):a973, 2003. e-Pub 2003.
      119. Chen H, Choudhury BD, Cohen DM, Craig SW. Development of FRET probes that monitor ligand-dependent change in vinculin conformation. Molecular biology of the cell(14 suppl):63a, 2003. e-Pub 2003.
      120. Chen H, Craig SW. Actin, PIP2 and vinculin head domain produce distinct conformations of vinculin tail revealed by FRET. Molecular biology of the cell(13 suppl):340a, 2002. e-Pub 2002.
      121. Chen H, Bamburg JR. Effects of latrunculin A and jasplakinolide on the interaction between ADF/cofilin and G- and F-actin. Molecular biology of the cell(12 suppl):155a, 2001. e-Pub 2001.
      122. Chen H, Sneider JM, Bernstein BW, Boyle JA, Bamburg JR. Chick ADF and cofilin differentially regulate filament dynamics in a pH-dependent fashion. Molecular biology of the cell(11 suppl):561a, 2000. e-Pub 2000.
      123. Chen H, Bamburg JR. Comparative effects of chick ADF and chick cofilin on actin filament turnover. Molecular biology of the cell(10 suppl):157a, 1999. e-Pub 1999.
      124. Chen H, Bamburg JR. Do ADF and cofilin participate in different aspects of actin filament dynamics?. Molecular biology of the cell(9 suppl):141a, 1998. e-Pub 1998.
      125. Chen H, Kelly S, Tang A, Bamburg JR. Nature of the actin-bound nucleotide differentially influences the binding of ADF and cofilin to G-actin. The FASEB Journal(11(9)):A985, 1997. e-Pub 1997.
      126. Dai M, Chen H, Iorgulescu B, Alvarez H, Luthra R, Patel KP, Rashid A, Sura GH, Sweeney KJ, Toruner GA, Yang RK, Dang H, Lucas FS, Roy-Chowdhuri S. Unraveling the Nexus: Tumor Mutational Burden, PD-L1 Expression and Oncogene Specific Alterations in Cytology Specimens of Non-Small Cell Lung Cancer. USCAP.
      127. Wang L, Chen H, Fei A, Zhang YH, Middleton LP, Krishnamurthy S, Huo L, Sahin A, Ding Q. GATA3 and TRPS1 Expression in Follicular Dendritic Cell Sarcoma. USCAP.
      128. Alrohaibani A, Sweeney KJ, Krasniqi R, Ding Q, Huo L, Wu Y, Dhamne S, Luthra R, Lucas FS, Roy-Chowdhuri S, Routbort M, Patel KP, Yang RK, Arun B, Albarracin CT, Chen H. ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics. USCAP.
      129. Guerrouahen BS, Lucas FS, Wang W, Roy-Chowdhuri S, Suchko M, Sun B, Shah KP, Reddy N, Mantha G, Meric-Bernstam F, Chen H. Optimizing TROP2 Immunohistochemistry Scoring by Automated Quantitative Image Analysis for Generating Clinical Trial-Driven IHC Scores. USCAP.
      130. Sweeney KJ, Yang RK, Alrohaibani A, Krasniqi R, Roy-Chowdhuri S, Patel KP, Routbort M, Albarracin CT, Chen H. Recurring Genes in Fusions in Advanced Breast Carcinoma Detected by Next Generation Sequencing: Novel BCR and TMPRSS2 Gene Fusions. USCAP.
      131. Krasniqi R, Alrohaibani A, Sweeney KJ, Albarracin CT, Chen H. Tumor Mutational Burden High Breast Cancer: Correlation with Clinicopathological and Co-existing Molecular Characteristics. USCAP.
      132. Alrohaibani A, Krasniqi R, Sweeney KJ, Albarracin CT, Chen H. Clinicopathological and Molecular Characteristics of Metastatic Breast Cancer: Comparison of Metastatic Sites. USCAP.

      Book Chapters

      1. Chen H, Roy Chowdhuri S. Molecular Diagnostics and Testing. In: Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer. 1st. Wolters Kluwer, 2022.
      2. Wu Y, Chen H, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Pathology, Fourth Edition, 2020.
      3. Chen H. Microfluidics-Based PCR for Fusion Transcript Detection. In: Methods Mol Biol, 103-11, 2016.

      Books (edited and written)

      1. Ye Q, Klippel D, Albarracin CT, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton LP, Resetkova E, Sahin A, Sun H, Sweeney KJ, Symmans WF, Wu Y, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer, 2024.

      Letters to the Editor

      1. Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Reply to Lambros et al. Modern Pathology 31: 541-542, 2018.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 15, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top